199 related articles for article (PubMed ID: 27342974)
41. Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins.
Ahi YS; Zhang S; Thappeta Y; Denman A; Feizpour A; Gummuluru S; Reinhard B; Muriaux D; Fivash MJ; Rein A
mBio; 2016 Nov; 7(6):. PubMed ID: 27879338
[TBL] [Abstract][Full Text] [Related]
42. Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5alpha.
Malbec M; Pham QT; Plourde MB; Létourneau-Hogan A; Nepveu-Traversy ME; Berthoux L
Virology; 2010 Sep; 405(2):414-23. PubMed ID: 20619429
[TBL] [Abstract][Full Text] [Related]
43. Cooperative effect of gag proteins p12 and capsid during early events of murine leukemia virus replication.
Lee SK; Nagashima K; Hu WS
J Virol; 2005 Apr; 79(7):4159-69. PubMed ID: 15767417
[TBL] [Abstract][Full Text] [Related]
44. Both TRIM5alpha and TRIMCyp have only weak antiviral activity in canine D17 cells.
Bérubé J; Bouchard A; Berthoux L
Retrovirology; 2007 Sep; 4():68. PubMed ID: 17892575
[TBL] [Abstract][Full Text] [Related]
45. Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein.
Lee ES; Jin SY; Kang BK; Jung YT
J Virol Methods; 2019 Jun; 268():32-36. PubMed ID: 30898575
[TBL] [Abstract][Full Text] [Related]
46. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction.
Yap MW; Nisole S; Stoye JP
Curr Biol; 2005 Jan; 15(1):73-8. PubMed ID: 15649369
[TBL] [Abstract][Full Text] [Related]
47. SUMO-interacting motifs of human TRIM5α are important for antiviral activity.
Arriagada G; Muntean LN; Goff SP
PLoS Pathog; 2011 Apr; 7(4):e1002019. PubMed ID: 21490953
[TBL] [Abstract][Full Text] [Related]
48. Post-entry restriction of retroviral infections.
Towers GJ; Goff SP
AIDS Rev; 2003; 5(3):156-64. PubMed ID: 14598564
[TBL] [Abstract][Full Text] [Related]
49. Studies on the restriction of murine leukemia viruses by mouse APOBEC3.
Sanchez-Martinez S; Aloia AL; Harvin D; Mirro J; Gorelick RJ; Jern P; Coffin JM; Rein A
PLoS One; 2012; 7(5):e38190. PubMed ID: 22666481
[TBL] [Abstract][Full Text] [Related]
50. Residues in the murine leukemia virus capsid that differentially govern resistance to mouse Fv1 and human Ref1 restrictions.
Lassaux A; Sitbon M; Battini JL
J Virol; 2005 May; 79(10):6560-4. PubMed ID: 15858043
[TBL] [Abstract][Full Text] [Related]
51. Enhancer-deficient amphotropic murine leukemia virus and recombinants with heterologous transcription elements can be efficiently amplified and detected in Mus dunni fibroblasts.
Reuss FU; Berdel B; Heber R; Ploss M
Gene Ther; 2002 Sep; 9(17):1183-8. PubMed ID: 12170382
[TBL] [Abstract][Full Text] [Related]
52. Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains.
Tailor CS; Kabat D
J Virol; 1997 Dec; 71(12):9383-91. PubMed ID: 9371598
[TBL] [Abstract][Full Text] [Related]
53. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells.
Patience C; Takeuchi Y; Cosset FL; Weiss RA
J Virol; 1998 Apr; 72(4):2671-6. PubMed ID: 9525584
[TBL] [Abstract][Full Text] [Related]
54. Capsid processing requirements for abrogation of Fv1 and Ref1 restriction.
Dodding MP; Bock M; Yap MW; Stoye JP
J Virol; 2005 Aug; 79(16):10571-7. PubMed ID: 16051849
[TBL] [Abstract][Full Text] [Related]
55. The nucleocapsid domain is responsible for the ability of spleen necrosis virus (SNV) Gag polyprotein to package both SNV and murine leukemia virus RNA.
Certo JL; Kabdulov TO; Paulson ML; Anderson JA; Hu WS
J Virol; 1999 Nov; 73(11):9170-7. PubMed ID: 10516024
[TBL] [Abstract][Full Text] [Related]
56. Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction.
Maillard PV; Zoete V; Michielin O; Trono D
J Biol Chem; 2011 Mar; 286(10):8128-8140. PubMed ID: 21169362
[TBL] [Abstract][Full Text] [Related]
57. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients.
Stitz J; Steidl S; Merget-Millitzer H; König R; Müller P; Nocken F; Engelstädter M; Bobkova M; Schmitt I; Kurth R; Buchholz CJ; Cichutek K
Virology; 2000 Feb; 267(2):229-36. PubMed ID: 10662618
[TBL] [Abstract][Full Text] [Related]
58. Role of Human TRIM5α in Intrinsic Immunity.
Nakayama EE; Shioda T
Front Microbiol; 2012; 3():97. PubMed ID: 22435067
[TBL] [Abstract][Full Text] [Related]
59. Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha.
Perron MJ; Stremlau M; Sodroski J
J Virol; 2006 Jun; 80(11):5631-6. PubMed ID: 16699044
[TBL] [Abstract][Full Text] [Related]
60. Association of TRIMCyp and TRIM5α from assam macaques leads to a functional trade-off between HIV-1 and N-MLV inhibition.
Mu D; Zhu JW; Liu FL; Zheng HY; Zheng YT
Sci China Life Sci; 2018 Aug; 61(8):954-965. PubMed ID: 29705873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
